

## Zoono Group Limited (ASX: ZNO) ASX ANNOUNCEMENT

9 May 2023

### ASIC Approval of Nominee for Rights Issue

Zoono Group Limited (**Company**) (ASX: ZNO) refers to the non-renounceable entitlement issue announced to ASX on 26 April 2023 for an offer of one (1) New Share for every four (4) existing Shares held by eligible shareholders on the Record Date, at an issue price of \$0.05 per New Share, together with one (1) free New Option for every three (3) New Shares applied for and issued, to raise up to \$2,102,289 (before costs) (**Rights Issue**).

As noted in the announcements, the Company decided not to extend the Rights Issue to shareholders with registered addresses outside of Australia and New Zealand (**Ineligible Shareholders**) and, subject to Australian Securities and Investments Commission's (**ASIC**) approval, appointed CCZ Equities Australia Pty Ltd to act as nominee for Ineligible Shareholders and to arrange the potential sale of entitlements which would have been offered to them had they been eligible to participate in the Entitlement Offer.

ASIC has now approved the appointment of CCZ Equities Australia Pty Ltd to act as the nominee for Ineligible Shareholders in relation to the Rights Issue under section 615 of the Corporations Act 2001 (*Cth*).

This announcement has been authorised and approved for release to ASX by the Company Secretary of Zoono Group Limited.

### For further information, please contact:

#### Zoono Group Limited

Paul Hyslop

Group MD

M: +64 21 659 977

E: [paul.hyslop@zoono.com](mailto:paul.hyslop@zoono.com)

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: [paul.ravlich@zoono.com](mailto:paul.ravlich@zoono.com)

### About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'ZOONO molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the Company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: [www.zoono.com](http://www.zoono.com)